argenx ARGX has outperformed the market over the past 5 years by 12.84% on an annualized basis producing an average annual return of 26.74%. Currently, argenx has a market capitalization of $46.69 billion.

August 28, 2025Amsterdam, the Netherlands - argenx ( Euronext & Nasdaq: ARGX ) , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor ...

argenx ARGX has outperformed the market over the past 5 years by 12.66% on an annualized basis producing an average annual return of 25.56%. Currently, argenx has a market capitalization of $43.33 billion.

ADAPT SERON data suggest FcRN inhibition could benefit seronegative gMG patients. Vyvgart sales are projected to grow 39% YoY to $2.93 billion in 2025, with TAM expanding 18% by 2030. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →

Vyvgart improved MG-ADL scores in seronegative gMG patients in Phase 3 ADAPT SERON trial. Argenx plans to file for FDA label expansion by late 2025. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →